Pasithea Therapeutics Corp. (KTTA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pasithea Therapeutics Corp. (KTTA:NASDAQ), powered by AI.

Current Price
$0.51
P/E Ratio
-0.0
Market Cap
559,002
Sector
Healthcare
What is the Pasithea Therapeutics Corp. stock price forecast?

Pasithea Therapeutics Corp. is currently trading at $0.51. View real-time AI analysis on Alpha Lenz.

What is Pasithea Therapeutics Corp. insider trading activity?

View the latest insider trading data for Pasithea Therapeutics Corp. on Alpha Lenz.

What is Pasithea Therapeutics Corp.'s P/E ratio?

Pasithea Therapeutics Corp.'s P/E ratio is -0.0.

Pasithea Therapeutics Corp.

NASDAQ · KTTA
$0.51-0.05(-8.93%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Pasithea Therapeutics Corp.'s future dividend policy...
Alpha Chat Insight

Pasithea Therapeutics Corp. trades at a P/E of -0.0 (undervalued) with modest ROE of -72.8%.

Ask for details

Company Overview

Pasithea Therapeutics Corp. is a biotechnology company specializing in the research and development of advanced therapeutics for psychiatry and neurology. The company's primary focus lies in discovering innovative solutions for mental health disorders, leveraging cutting-edge science and technology to address unmet medical needs. Pasithea Therapeutics aims to transform the treatment landscape for conditions such as depression, anxiety, and other psychiatric disorders. Driven by a mission to revolutionize mental health care, Pasithea Therapeutics engages in developing proprietary drug candidates and exploring the potential of psychedelic compounds. The company operates within the broader healthcare and biopharmaceutical sectors, contributing to significant advancements in medical research and treatment modalities. Its innovative approach positions it at the forefront of a rapidly evolving industry that seeks to tackle complex mental health challenges. Pasithea Therapeutics is notably committed to expanding therapeutic options, providing an impactful presence in the market as healthcare systems globally strive to enhance mental health outcomes. Through collaboration with research institutions and strategic partnerships, the company plays a vital role in pushing the boundaries of medical science for psychiatry and neurology.

CEODr. Tiago Reis Marques M.D., Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees4

Company Statistics

FY 2024

Profile

$559.00KMarket Cap
$0.00Revenue
0.00Shares Out
4Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-0.04P/E
0.04P/B
N/AEV/Sales
0.47EV/EBITDA
-0.04P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-65.93%ROA
-72.83%ROE
-67.56%ROIC

Financial Health

$6.92MCash & Cash Equivalents
$-5.64MNet Debt
8.67%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Pasithea Therapeutics Corp. (ticker: KTTA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 4 employees. Market cap is $559,002.

The current price is $0.51 with a P/E ratio of -0.04x and P/B of 0.04x.

ROE is -72.83%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Pasithea Therapeutics Corp. (KTTA) Stock Forecast 2026 $0.51 — Price, Financials & Analyst Targets | Alpha Lenz